{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-25-000058","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.125642+00:00","generated_at":"2026-05-22T07:23:49.311551+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veracyte Q1 2025 revenue $114.5M (+18% YoY); net income $7.0M, Decipher revenue up 33%","bullets":["Total revenue $114.5M (+18% YoY); testing revenue $107.3M (+19%); total test volume 40,655 (+22%).","Decipher revenue $66.6M (+33%); Afirma revenue $38.3M (+6%); Decipher volume ~22,600 (+37%).","Net income $7.0M (6.2% of revenue); adjusted EBITDA $24.7M (21.6% of revenue).","Launched limited access to Decipher for metastatic prostate cancer, expanding addressable population.","Cash and short-term investments $287.4M; generated $5.4M cash from ops."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-25-000058","json":"https://secwatch.observer/filing/0001384101-25-000058.json","markdown":"https://secwatch.observer/filing/0001384101-25-000058.md","text":"https://secwatch.observer/filing/0001384101-25-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410125000058/0001384101-25-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410125000058/vcyt-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:23:49.311551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}